Third-quarter 2026 earnings call, November 3, 2026: revenue up 68%, FY guide raised to $121 million-$123 million
Alamar Biosciences reported third-quarter revenue of $33.5 million, up 68% from $19.9 million a year earlier, and raised its full-year 2026 revenue guidance to $121 million to $123 million from $116 million to $120 million. The new midpoint implies 64% annual growth. The more important development for investors is what accompanied the numbers: two large sample-scale wins, a first-time majority-biopharma revenue mix, and a clearer timeline for the company's push into clinical diagnostics. The caveat is that the raised guide leaves little room for sequential growth in the fourth quarter, a point analysts pressed on during the call.
Two large-scale wins validate the low-abundance proteome thesis
Alamar was selected, together with Nightingale Health, to deliver UK Biobank's Vanguard study of blood-based biomarkers for neurodegeneration. The study will run Alamar's NULISA technology in Nightingale's laboratories, profiling 220 neurologically relevant proteins across 80,000 blood samples from individuals who were healthy at enrollment. It will be the first time brain-derived and other low-abundance proteins are measured in the UK Biobank, and management expects it to produce the first definitive proteomics dataset for Parkinson's disease. Sample processing begins in the fourth quarter, with a ramp in 2027 and completion expected by the end of 2027. Data will be integrated with the biobank's imaging, genetic and longitudinal health records and made available to approved researchers worldwide.
The second win is a strategic scientific partnership with GSK, under which Alamar will profile more than 60,000 serum samples using its Immune 340 and Neuro 220 panels. The work spans respiratory, liver, kidney, neurological and autoimmune conditions, using real-world healthcare data, with a focus on biological subtyping and treatment response. Notably, the agreement allows Alamar to potentially develop and commercialize novel protein signatures of its own. Work begins in the first quarter of 2027, though management declined to give a completion timeline. CEO Yuling Luo framed the deal as evidence that "major pharma recognize the value of platforms beyond neurodegeneration."
Investors should note what management did not provide. Neither project's revenue will be broken out, and the company declined to guide to sample volumes per quarter, noting that throughput "can fluctuate quarter-to-quarter" and that projects can have ramp-up periods. Q4 UK Biobank contributions are already embedded in the new guide, and the GSK work is in internal forecasts only "on a risk-adjusted basis." Both programs are therefore better read as 2027 growth drivers and credibility markers than as quantifiable near-term revenue.
Why sensitivity matters: the AI argument and the multi-marker thesis
Luo offered an argument that is likely to matter more over time than any single quarter. Machine learning models built on proteomic data learn disease signatures by comparing them against healthy samples, where low-abundance proteins are at their lowest levels. When a platform cannot detect a protein, "that missing value is typically filled in statistically, and a model trained on that data risks learning patterns that reflect the gaps in the measurement rather than real biology." Alamar believes data generated on NULISA will become more valuable as AI becomes central to biomarker discovery. This is a company assertion rather than something demonstrated in the quarter, but it explains why the UK Biobank's healthy-at-enrollment design plays to the platform's strengths.
Management also pointed to supporting academic evidence. A Lancet Neurology study from Washington University used the CNS 120 panel to measure 130 proteins across nearly 2,400 samples from patients on lecanemab and untreated controls, using just 25 microliters of plasma per sample. Of the 130 biomarkers, 34 changed significantly during therapy, not all in the same direction, and brain-derived tau accounted for 4 of the top 5 markers separating treated patients from controls. An independent Emory University study identified a 10-protein signature that distinguished ALS from healthy controls with 98% balanced accuracy in validation, compared with about 90% for neurofilament light alone. The cumulative publication and preprint count now exceeds 200, with more than 35 added in the quarter.
Biopharma overtakes academia; consumables lead
Consumables revenue rose 79% to $17.8 million and made up 53% of the total. Instrument revenue was $8.5 million, up 50%, and service and other revenue was $7.2 million. By customer, biopharma accounted for 49% of revenue, up from 42% in the second quarter and the largest share for the first time. Academic and research institutions made up 44% and distributors 7%. Geographically, the Americas contributed 70%, EMEA 20% and APAC 10%. CFO Justin McAnear noted that biopharma customers "tend to run larger, more sustained studies that drive meaningful consumables pull-through over time."
On placements, management reiterated that it remains on track to add at least 100 instruments in 2026 and to keep annual pull-through per instrument above $400,000. Placements split roughly 50-50 between academic and biopharma customers. Most Q3 placements went to new customers, but the quarter also set a record for instruments sold to existing customers' new labs. The company will update installed base and pull-through metrics only annually, with the next disclosure on the year-end call, which limits investors' ability to track unit economics in the interim. Management also conceded that placement timing is "harder to predict" given the long sales cycle tied to instrument cost.
Quality of the beat and a cautious fourth quarter
The quarter was flattered by the Technology Access Program, or TAP. McAnear said it delivered its largest quarterly revenue to date, driven by large custom assay development projects and population studies completed within the quarter, and that this will not repeat at the same level in Q4. Some revenue shifted into Q3 from Q4. The guide therefore assumes TAP declines sequentially, with higher consumables offsetting it.
Leerink's Puneet Souda noted that even the top of the new range implies roughly flat sequential revenue, despite UK Biobank beginning, seasonally stronger Q4 placements and TAP-to-consumables conversion. Management called its approach "prudent" and said the top end would represent a sequential increase. Given a Q3 beat of nearly $4 million and a guide raised by a similar amount, the outlook looks conservative, but investors are being asked to take that on trust.
Gross margin hits a record, though not a floor
Gross margin reached 61.5%, up from 59.7% a year ago, and gross profit was $20.6 million. McAnear attributed the gain to lower instrument costs, higher consumables selling prices, better TAP margins and mix shift toward consumables. He cautioned against treating the level as sustainable: TAP carries a relatively fixed team base, so when it overdelivers, "you can get a benefit to the gross margin," and "I would be careful about treating the margin that we had in Q3 as a floor." With TAP stepping down in Q4, some give-back is plausible, though management expects margins to trend upward over time as consumables scale.
Losses widen as spending accelerates
Operating expenses rose to $35.8 million from $19.8 million. R&D was $16.2 million, up 58%, on lab supplies for the expanding panel menu and personnel. SG&A was $19.6 million, up 105%, reflecting headcount and higher legal and accounting costs as a newly public company. Operating loss widened to $15.1 million from $7.9 million, including $3.9 million of stock-based compensation versus $0.7 million a year ago. Net loss was $13.3 million versus $8.0 million.
Spending will climb further in the fourth quarter as the company pulls forward R&D projects originally planned for 2027, which management described as multiyear programs supporting its content and instrument road map. The company ended September with $231.5 million in cash, equivalents, short-term investments and restricted cash, and plans to use it for commercial expansion, manufacturing capacity and R&D. Management reiterated a "disciplined path to profitability," but offered no timetable, and opex growth is currently outpacing revenue growth.
Clinical ambitions: ARGO HT/DX filing targeted for end of 2027
Alamar plans to submit its ARGO HT/DX clinical instrument for FDA marketing authorization by the end of next year, accompanied by a test designed to showcase the platform's sensitivity and multiplexing. The strategy is to supply the hardware and operating system while partners with disease expertise, regulatory experience, reimbursement pathways and commercial channels build the diagnostic applications. Luo likened the expected transition from single-marker immunoassays to multi-marker protein signatures to the move from PCR to next-generation sequencing two decades ago. Former GRAIL CEO and Illumina COO Bob Ragusa joined the board, a signal of the clinical direction. Management said it expects to establish diagnostic partnerships in 2027, but none have been named. The research market is estimated at $11 billion over the next decade, while the clinical opportunity remains unquantified and unproven.
Leadership transition
President Todd White, formerly CFO and Chief Business Officer, will retire at year-end and serve as an adviser through June 2027. The company also added a general counsel and a chief people officer. For 2027, management's stated priorities are expanding the installed base, launching a multiplex panel in a new disease area, submitting ARGO HT/DX and establishing diagnostic partnerships.